Potential treatment for depression researched by Northumberland mental health trust

Northumberland, Tyne and Wear NHS Foundation Trust (NTW) is carrying out scientific research into a potential new treatment for depression.

Friday, 21st December 2018, 10:03 am
Brought to you by the Berwick Advertiser team.

It is one of three clinical sites in the UK and around 18 worldwide that are taking part in a multinational research study into the safety and efficacy of psilocybin therapy in people with treatment resistant depression (TRD).

Psilocybin is a naturally occurring chemical found in particular species of mushrooms, sometimes referred to as magic mushrooms. It is one of a group of drugs known as psychedelics which may have the potential to change perceptions.

Professor Hamish McAllister Williams, principal investigator for NTW said: “The data we have currently suggests psilocybin therapy may be a novel and very different treatment for depression. However, more evidence is required before it is used clinically.”

The psilocybin being used in the study has been chemically synthesised to good manufacturing practice (GMP) standards by the study sponsor, COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health.

Sign up to our daily newsletter

The i newsletter cut through the noise

Participants who are currently suffering from at least moderately severe depression for between three months and two years, and have tried between two and four antidepressant treatments in this episode will be recruited into the study. Any still on antidepressants will have these tapered off prior to the administration of a single dose of psilocybin. They will be supported by two trained facilitators for six hours on the dosing day, in a quiet safe clinical environment. Preparation will occur over three weeks prior to treatment and follow up visits will last 12 weeks.

A recent preliminary, open-label study has shown significant improvement in depressive symptoms following psilocybin administration with psychological support. Over 40% of participant’s sustained response at three months and 32% had no need for further antidepressants or therapy at one year.

Professor McAllister Williams, added: “This exciting new study will provide valuable effectiveness and safety information that will help us progress the development of the treatment and its potential introduction into clinical practice. If the study is positive, this will have implications for many people with depression who have not responded to conventional antidepressants.”